IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)

OBJECTIVE: To assess safety and efficacy within a multi-center trial the H3.3K27M specific peptide vaccine with poly-ICLC in HLA-A02.01(+) patients diagnosed with H3.3K27M(+) DMGs. METHODS: After focal radiation therapy, participants 3–21 years of age were enrolled into two strata. Stratum A: newly...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Sabine, Taitt, Jared, Bonner, Erin, Lulla, Rishi, Goldman, Stewart, Banerjee, Anu, Chi, Susan, Whipple, Nicholas S, Crawford, John, Gauvain, Karen, Nazemi, Kellie, Watchmaker, Payal, Nejo, Takahide, Okada, Kaori, Butterfield, Lisa H, Nazarian, Javad, Villaneuva-Meyer, Javier, Molinaro, Annette M, Prados, Michael, Okada, Hideho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715716/
http://dx.doi.org/10.1093/neuonc/noaa222.385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715716/
http://dx.doi.org/10.1093/neuonc/noaa222.385

Ejemplares similares